Sapient Capital LLC Cuts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sapient Capital LLC cut its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 56.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,540 shares of the biotechnology company's stock after selling 4,615 shares during the quarter. Sapient Capital LLC's holdings in Sarepta Therapeutics were worth $430,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Simplify Asset Management Inc. increased its stake in shares of Sarepta Therapeutics by 84.6% during the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company's stock worth $24,105,000 after purchasing an additional 88,474 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock worth $211,910,000 after purchasing an additional 44,306 shares during the last quarter. Summit Partners Public Asset Management LLC increased its stake in shares of Sarepta Therapeutics by 547.9% during the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company's stock worth $17,250,000 after purchasing an additional 116,800 shares during the last quarter. Larson Financial Group LLC increased its stake in shares of Sarepta Therapeutics by 1,649.8% during the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company's stock worth $1,093,000 after purchasing an additional 8,249 shares during the last quarter. Finally, abrdn plc increased its stake in shares of Sarepta Therapeutics by 30.7% during the 3rd quarter. abrdn plc now owns 431,098 shares of the biotechnology company's stock worth $53,935,000 after purchasing an additional 101,253 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Insider Activity at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares in the company, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now owns 22,840 shares of the company's stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock traded down $1.51 on Friday, reaching $107.95. 630,697 shares of the stock were exchanged, compared to its average volume of 847,020. The firm's 50 day moving average is $119.42 and its 200-day moving average is $124.72. Sarepta Therapeutics, Inc. has a one year low of $102.15 and a one year high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a market cap of $10.31 billion, a PE ratio of 86.36 and a beta of 0.75.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a research note on Monday, January 27th. Guggenheim upped their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics in a research note on Tuesday. They issued a "hold" rating and a $136.00 price target on the stock. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and upped their price target for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 21st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $176.77.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.